16.88 0.40 (2.43%)

62.94% Fall from 52W High

213.3K XNAS Volume

XNAS 20 Mar, 2025 5:30 PM (EDT)



Insider Trading disclosures for Tourmaline Bio Inc

The latest disclosure was made by Sandeep C. Kulkarni in Tourmaline Bio Inc where a trade of 226,000 Employee Stock Option (Right to Buy) done was reported to US exchanges on Feb. 3, 2025.

Insider trading is the trading of a company’s securities by individuals with access to confidential or material non-public information about the company. A company is required to report trading by corporate officers, directors, or other company members with significant access to privileged information to the Securities and Exchange Commission (SEC).

Client Name Client Category Action Reported to Exchange Quantity Post Transaction Holding Traded % Avg. Price Value Security Type
Sandeep C. Kulkarni Director, CEO Grant, award, or other acquisition of securities at price $ 0.00 per share. 03 Feb 2025 226,000 226,000 - - Employee Stock Option (Right to Buy)
W. Bradford Middlekauff CBO, GC and Secretary Grant, award, or other acquisition of securities at price $ 0.00 per share. 27 Jan 2025 58,000 58,000 - - Employee Stock Option (Right to Buy)
Susan Dana Jones Chief Technology Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 27 Jan 2025 58,000 58,000 - - Employee Stock Option (Right to Buy)
Kevin Bruce Johnson Chief Regulatory Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 27 Jan 2025 58,000 58,000 - - Employee Stock Option (Right to Buy)
Ryan F. Robinson Chief Financial Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 27 Jan 2025 58,000 58,000 - - Employee Stock Option (Right to Buy)
Sandeep C. Kulkarni Director, CEO Purchase of securities on an exchange or from another person at price $ 14.85 per share. 21 Aug 2024 1,779 7,000 - 14.8 26,418 Common Stock
Sandeep C. Kulkarni Director, CEO Purchase of securities on an exchange or from another person at price $ 13.79 per share. 16 Aug 2024 5,221 5,221 - 13.8 71,998 Common Stock
Ryan F. Robinson Chief Financial Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 25 Jun 2024 76,400 76,400 - - Employee Stock Option (Right to Buy)
Mark D. Mcdade Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 05 Jun 2024 10,000 10,000 - - Stock Option (Right to Buy)
Clay B. Siegall Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 05 Jun 2024 15,000 15,000 - - Stock Option (Right to Buy)
Sapna Srivastava Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 05 Jun 2024 10,000 10,000 - - Stock Option (Right to Buy)
Caley Castelein Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 05 Jun 2024 10,000 10,000 - - Stock Option (Right to Buy)
Aaron Kantoff Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 05 Jun 2024 10,000 10,000 - - Stock Option (Right to Buy)
Parvinder Thiara Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 05 Jun 2024 10,000 10,000 - - Stock Option (Right to Buy)
Mark D. Mcdade Director Purchase of securities on an exchange or from another person at price $ 32.50 per share. 29 Jan 2024 100,000 448,431 - 32.5 3,250,000 Common Stock
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc  
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges
View All The Insider Trades disclosures